Ironwood Pharma (IRWD) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update
May 1, 2018 7:55 AM EDTFirst quarter revenue increased 33% year-over-year to $69 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $159 million and commercial margin of 63%
IW-3718 Phase III program expected to initiate in the third quarter of 2018
Phase II sGC programs, praliciguat and olinciguat (IW-1701) continue to progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:... More
